The development for emerging biomarkers of lymphangioleiomyomatosis.

Autor: Huang L; Department of Pulmonary and Critical Care Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China.; Research Unit of Respiratory Disease, Central South University, Changsha, Hunan, 410011, China.; Clinical Medical Research Center for Pulmonary and Critical Care Medicine in Hunan Province, Changsha, 410011, China.; Diagnosis and Treatment Center of Respiratory Disease, Central South University, Changsha, Hunan, 410011, China., Xiao Y; Department of Pulmonary and Critical Care Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China.; Research Unit of Respiratory Disease, Central South University, Changsha, Hunan, 410011, China.; Clinical Medical Research Center for Pulmonary and Critical Care Medicine in Hunan Province, Changsha, 410011, China.; Diagnosis and Treatment Center of Respiratory Disease, Central South University, Changsha, Hunan, 410011, China., Yang L; Department of Pulmonary and Critical Care Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China.; Research Unit of Respiratory Disease, Central South University, Changsha, Hunan, 410011, China.; Clinical Medical Research Center for Pulmonary and Critical Care Medicine in Hunan Province, Changsha, 410011, China.; Diagnosis and Treatment Center of Respiratory Disease, Central South University, Changsha, Hunan, 410011, China., Ren S; Department of Pulmonary and Critical Care Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China. syren@csu.edu.cn.; Research Unit of Respiratory Disease, Central South University, Changsha, Hunan, 410011, China. syren@csu.edu.cn.; Clinical Medical Research Center for Pulmonary and Critical Care Medicine in Hunan Province, Changsha, 410011, China. syren@csu.edu.cn.; Diagnosis and Treatment Center of Respiratory Disease, Central South University, Changsha, Hunan, 410011, China. syren@csu.edu.cn.
Jazyk: angličtina
Zdroj: Orphanet journal of rare diseases [Orphanet J Rare Dis] 2024 Nov 29; Vol. 19 (1), pp. 445. Date of Electronic Publication: 2024 Nov 29.
DOI: 10.1186/s13023-024-03455-9
Abstrakt: Lymphangioleiomyomatosis (LAM) is a rare, slowly progressing, low-grade metastatic tumor primarily affecting women. Currently, vascular endothelial growth factor-D (VEGF-D) is the only validated diagnostic biomarker, enabling diagnosis of LAM without the need for lung biopsy in appropriate clinical settings. However, VEGF-D concentrations are normal in about 30% of patients, rendering it insufficient for diagnosing all cases of LAM. There remains a need to identify more non-invasive, safe, sensitive, and specific biomarkers associated with LAM. Therefore, it is imperative to explore novel non-invasive, safe, and specific diagnostic methods for LAM. This article aims to review biomarkers associated with LAM, including potential biomarkers newly discovered or showing advancements in classical biomarkers widely used in LAM, and discuss their application in LAM diagnosis, assessment of disease severity, prediction of treatment response, and prognosis. （LAM） 、，。，-D （VEGF-D） ， LAM。， 30% VEGF-D ， LAM 。 LAM 、、。，、 LAM 。 LAM ， LAM ， LAM 、、。.
Competing Interests: Declarations. Ethics approval and consent to participate: Not applicable. Consent for publication: Written informed consent was given by the participants, and all the participants have given the consent for their images. Competing interests: The authors declare no conflict of interest.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje